Single-nucleotide polymorphisms of vascular endothelial growth factor in psoriasis of early onset.
about
Vascular endothelial growth factor inhibitors: investigational therapies for the treatment of psoriasisAssociation analyses identify six new psoriasis susceptibility loci in the Chinese populationVEGF, FGF1, FGF2 and EGF gene polymorphisms and psoriatic arthritis.Expression of Angiogenic Factors in Psoriasis VulgarisIL-33 augments substance P-induced VEGF secretion from human mast cells and is increased in psoriatic skin.Halting angiogenesis by non-viral somatic gene therapy alleviates psoriasis and murine psoriasiform skin lesions.In vivo pharmacological disease models for psoriasis and atopic dermatitis in drug discovery.Inhibition of chronic and acute skin inflammation by treatment with a vascular endothelial growth factor receptor tyrosine kinase inhibitorAssociation of vascular endothelial growth factor (VEGF) +405 g>c polymorphism with endometriosis in an Iranian populationOverexpression of vascular endothelial growth factor (VEGF) receptors on keratinocytes in psoriasis: regulated by calcium independent of VEGFSystemic anti-VEGF treatment strongly reduces skin inflammation in a mouse model of psoriasis.Angiogenesis drives psoriasis pathogenesis.Discovery and functional assessment of gene variants in the vascular endothelial growth factor pathwayThe role of angiogenesis in the pathogenesis of psoriasis.Four polymorphisms of VEGF (+405C>G, -460T>C, -2578C>A, and -1154G>A) in susceptibility to psoriasis: a meta-analysis.Investigational VEGF antagonists for psoriasis.Pharmacogenetics of topical and systemic treatment of psoriasis.Polymorphism of VEGF gene in susceptibility to chronic immune-mediated inflammatory diseases: a meta-analysis.VEGF involvement in psoriasis.Novel investigational vascular endothelial growth factor (VEGF) receptor antagonists for psoriasis.VEGFR-3 Expression in Oral Lichen PlanusRemission of psoriasis and psoriatic arthritis during bevacizumab therapy for renal cell cancer.Impaired nuclear translocation of glucocorticoid receptors: novel findings from psoriatic epidermal keratinocytes.Angiogenesis Dysregulation in Psoriatic Arthritis: Molecular Mechanisms.Genetic Risk Factors for Psoriasis in Turkish Population: -1540 C/A, -1512 Ins18, and +405 C/G Polymorphisms within the Vascular Endothelial Growth Factor Gene.Vascular endothelial growth factor +405 C/G polymorphism is highly associated with an increased risk of endometriosis in Turkish women.Digestive system in psoriasis: an update.Vascular endothelial growth factor gene polymorphism prevalence in patients with diabetic macular oedema and its correlation with anti-vascular endothelial growth factor treatment outcomes.Excessive angiogenesis associated with psoriasis as a cause for cardiovascular ischaemia.IL-36γ Is a Strong Inducer of IL-23 in Psoriatic Cells and Activates Angiogenesis.Vascular endothelial growth factor (VEGF) +405 C/G polymorphism is associated with essential hypertension in a population from Tehran of Iran.Association of psoriasis with the VEGF gene polymorphism in the northern Polish population.The Role of Forkhead Box Class O3A and SIRT1 Gene Variants in Early-Onset Psoriasis.Geographic tongue and fissured tongue in 348 patients with psoriasis: correlation with disease severity.Vascular endothelial growth factor gene polymorphisms increase the risk to develop psoriasisComparison of apatinib and capecitabine (Xeloda) with capecitabine (Xeloda) in advanced triple-negative breast cancer as third-line therapy: A retrospective study
P2860
Q22305863-2649AB7C-CB88-42FC-AD47-6CC0A7510C2DQ24630768-ADED2014-D915-4BC6-B8EF-3C1520EED236Q33268240-EAA5EA60-1F4D-4AC8-BE8E-0321FEA2E230Q33666312-114A3A21-DF24-4132-A0B6-B25D74B5D626Q33732911-85FFFC79-5B6F-45C2-8A65-8434BA2FEACAQ34428875-CBF220C9-9E08-4A40-B11D-50EDCF65C96BQ36570707-11BD887B-FADE-4027-80D9-651BA64F99CFQ36734939-B5F0653F-DD52-4C82-A6E8-433EC65CC579Q37035051-B4C8ABB3-BE77-41B5-A9F4-221F9B6DADBDQ37293884-DB81C8C8-6D6B-43F3-8D62-390B1BB25386Q37482178-B865C8F9-770F-4E24-868C-4518C83AC0C0Q37534974-3D2D701D-82F7-4610-A51C-2B3D731FF030Q37604560-7349AB9B-3E6F-4226-B6C0-B3B2DE7F3705Q37622941-D1259B90-0010-46F2-8F24-8EA911FCB180Q37667504-551441A3-9C85-4235-BB7A-54A733541D5CQ37956733-B2D07C59-A39A-402B-B22D-1803B1ADE2CEQ38148599-40615346-077F-4BE1-879B-91606344C357Q38389715-DB983742-E8AB-41B4-82AC-38D6C6CC65ADQ38648336-267BF12B-C94F-4F6E-A6A6-AE5C0A5733E9Q38728552-8DEC97A9-9748-43E2-A35D-1E3DE8E6D2ACQ38874700-3F87F957-E86C-4EC1-B265-19ECC39ED2EAQ39080285-16C34B98-7F4A-443A-A3DD-0AFCCA2FF04EQ39207790-1061D6F7-311A-4537-A9AB-3BEF10CEB52DQ41208827-B4F5B792-5FD0-4BBD-8252-7DA8285EDC2FQ42087723-06EF7BD7-088D-4622-A609-F4F50771E817Q44346025-1AC1FE03-82C1-48C9-BC43-B3659213BC2EQ46466020-2AEEFBC7-4161-4365-A32A-3B016D1CA4BEQ47828789-8A4A0BDA-DFB6-4603-8EAC-EA36FB1AAFC4Q48280209-98FD61C7-503B-4BB0-92DB-BE961367C568Q52802857-D49A6EAB-C2A9-47A1-9370-EF4A2583EFC8Q54331504-E0671722-83D6-44CB-9B81-9F3C51FAFDE7Q54333710-F89004E6-DF18-480A-9A54-2E9A2E012447Q55555049-A20DAF13-9D76-42C3-AD73-72889C13148FQ55711065-AEA02E1C-A030-49B4-8DF9-C39FEDDAF16DQ57613985-6F69EC61-5A47-418A-B968-5FEABB12444DQ58759141-1A050394-B154-4317-86DB-0C1A3D5923F8
P2860
Single-nucleotide polymorphisms of vascular endothelial growth factor in psoriasis of early onset.
description
2004 nî lūn-bûn
@nan
2004年の論文
@ja
2004年論文
@yue
2004年論文
@zh-hant
2004年論文
@zh-hk
2004年論文
@zh-mo
2004年論文
@zh-tw
2004年论文
@wuu
2004年论文
@zh
2004年论文
@zh-cn
name
Single-nucleotide polymorphism ...... r in psoriasis of early onset.
@en
type
label
Single-nucleotide polymorphism ...... r in psoriasis of early onset.
@en
prefLabel
Single-nucleotide polymorphism ...... r in psoriasis of early onset.
@en
P50
P1476
Single-nucleotide polymorphism ...... or in psoriasis of early onset
@en
P2093
Angela M Summers
Monica Bhushan
P304
P356
10.1046/J.0022-202X.2003.22107.X
P407
P577
2004-01-01T00:00:00Z
P6179
1050028003